 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456 |
- |||| Signifor LAR (pasireotide long acting release) / Recordati
Enrollment open: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (clinicaltrials.gov) - Aug 26, 2013
P4, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting
- ||||| Signifor (pasireotide) / Recordati
New P2 trial, Combination therapy: Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease (clinicaltrials.gov) - Jul 31, 2013
P2, N=128, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| Signifor (pasireotide) / Recordati
Trial completion: Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease (clinicaltrials.gov) - Jul 30, 2013
P3, N=165, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Signifor (pasireotide) / Recordati
Enrollment change: Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease (clinicaltrials.gov) - Jul 24, 2013
P2, N=19, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=26 --> 19
- | Signifor (pasireotide) / Recordati
Trial completion: Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease (clinicaltrials.gov) - Jul 24, 2013
P2, N=19, Completed, Sponsor: Novartis Pharmaceuticals
N=26 --> 19 Active, not recruiting --> Completed
- Signifor (pasireotide) / Recordati
New P2 trial: Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome (clinicaltrials.gov) - Jul 8, 2013
P2, N=9, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
- Signifor (pasireotide) / Recordati
Trial completion: Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome (clinicaltrials.gov) - Jul 3, 2013
P2, N=9, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Signifor (pasireotide) / Recordati
Trial termination, Surgery: Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma (clinicaltrials.gov) - Mar 13, 2013
P2, N=2, Terminated, Sponsor: University of Utah
Not yet recruiting --> Completed Active, not recruiting --> Terminated; Original PI left and company withdrew support.
- Signifor (pasireotide) / Recordati
Enrollment change, Surgery: Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma (clinicaltrials.gov) - Mar 13, 2013
P2, N=2, Terminated, Sponsor: University of Utah
Active, not recruiting --> Terminated; Original PI left and company withdrew support. N=42 --> 2
- ||||| Signifor LAR (pasireotide long acting release) / Recordati
New P4 trial: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (clinicaltrials.gov) - Feb 18, 2013
P4, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
- Signifor (pasireotide) / Recordati
New P2 trial: Objective evaluation of the effects of pasireotide on gastrointestinal and colorectal transit times, rectal wall properties, and postprandial response in patients with carcinoid diarrhea Unders (EUDRACT) - Feb 11, 2013
P2, N=15, Ongoing, Sponsor: Klaus Krogh
- |||||| Signifor (pasireotide) / Recordati
Enrollment open: An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. (clinicaltrials.gov) - Nov 6, 2012
P3, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
N=42 --> 2 Available --> Recruiting
- ||||| Signifor (pasireotide) / Recordati
Enrollment change: Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess (clinicaltrials.gov) - Aug 16, 2012
P3, N=600, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Available --> Recruiting N=300 --> 600
- Signifor (pasireotide) / Recordati
New P2/3 trial: Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas (clinicaltrials.gov) - Jun 13, 2012
P2/3, N=30, Recruiting, Sponsor: Federal University of Rio de Janeiro
- ||| Signifor (pasireotide) / Recordati
Enrollment open: A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers (clinicaltrials.gov) - Jun 4, 2012
P1, N=64, Recruiting, Sponsor: Novartis Pharmaceuticals
N=300 --> 600 Not yet recruiting --> Recruiting
- Signifor (pasireotide) / Recordati
New P2 trial, Combination therapy: SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer (clinicaltrials.gov) - May 24, 2012
P2, N=19, Recruiting, Sponsor: Federico II University
- |||||||||| Signifor (pasireotide) / Recordati
New P3 trial: An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. (clinicaltrials.gov) - Apr 18, 2012
P3, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Signifor (pasireotide) / Recordati
New P1 trial: A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers (clinicaltrials.gov) - Apr 15, 2012
P1, N=64, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Signifor (pasireotide) / Recordati
Enrollment open: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Feb 8, 2012
P1/2, N=49, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Signifor (pasireotide) / Recordati
New P1/2 trial: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Nov 8, 2011
P1/2, N=49, Recruiting, Sponsor: Emory University
- Signifor (pasireotide) / Recordati
New P1/2 trial, Metastases: Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Oct 24, 2011
P1/2, N=24, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- | Signifor (pasireotide) / Recordati
New P2 trial: Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov) - Aug 14, 2011
P2, N=28, Recruiting, Sponsor: South Florida Veterans Affairs Foundation for Research and Education